dMCL1-2
| Code | Size | Price |
|---|
| TAR-T13657-5mg | 5mg | £2,641.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, which binds to MCL1 with a KD of 30 nM. dmcl-2 activates the apoptosis mechanism by degrading MCL1.
CAS:
2351218-88-5
Formula:
C61H66N10O12S
Molecular Weight:
1163.32
Purity:
0.98
SMILES:
CN(C)S(=O)(=O)N1CCN(CC1)c1ccc(OCc2c(c(C)nn2C)-c2cccc3c(CCCOc4cccc5ccccc45)c(C(O)=O)n(CCN4CCN(CC4)C(=O)COc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)c23)cc1
References
1. Papatzimas JW, et al. From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1). J Med Chem. 2019 Jun 13;62(11):5522-5540.